Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer

Dobilas, Arturas LU ; Leandersson, Pia LU orcid ; Chen, Yilun LU ; Alcaide, Miguel ; Brueffer, Christian LU orcid ; Saal, Lao LU orcid and Borgfeldt, Christer LU (2022) In International Journal of Gynecological Cancer 32(Suppl 2). p.405-405
Abstract
Introduction/Background
Circulating tumor DNA (ctDNA), which is shed from tumor cells into the blood, is a promising minimal-invasive method for cancer diagnostics and monitoring. The aim of this study was to evaluate preoperative ctDNA levels in the plasma of patients with ovarian cancer and correlate the levels to clinico-pathological parameters and patient outcome.

Methodology
Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples,... (More)
Introduction/Background
Circulating tumor DNA (ctDNA), which is shed from tumor cells into the blood, is a promising minimal-invasive method for cancer diagnostics and monitoring. The aim of this study was to evaluate preoperative ctDNA levels in the plasma of patients with ovarian cancer and correlate the levels to clinico-pathological parameters and patient outcome.

Methodology
Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples, obtained prior to surgery, to evaluate ctDNA levels in terms of mutant copy number/mL and variant allele frequency.

Results
Somatic mutations were found in 24 tumors, of which seven were from patients with borderline, and 17 with invasive cancer diagnosis. TP53 was the most frequently mutated gene. Fifteen of 24 patients had detectable ctDNA levels in pre-operative plasma. Plasma ctDNA mutant concentration increased with higher stage (p_trend (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Ovarian cancer, Gynecological cancer disease, Minimal residual disease, Liquid biopsy, ctDNA
in
International Journal of Gynecological Cancer
volume
32
issue
Suppl 2
article number
2022-RA-627-ESGO
pages
405 - 405
publisher
BMJ Publishing Group
ISSN
1048-891X
DOI
10.1136/ijgc-2022-ESGO.868
language
English
LU publication?
yes
id
e9a918a5-9d0c-4989-b8de-2b1beed6cf47
date added to LUP
2023-10-03 09:53:20
date last changed
2023-10-04 02:30:50
@misc{e9a918a5-9d0c-4989-b8de-2b1beed6cf47,
  abstract     = {{Introduction/Background<br/>Circulating tumor DNA (ctDNA), which is shed from tumor cells into the blood, is a promising minimal-invasive method for cancer diagnostics and monitoring. The aim of this study was to evaluate preoperative ctDNA levels in the plasma of patients with ovarian cancer and correlate the levels to clinico-pathological parameters and patient outcome.<br/><br/>Methodology<br/>Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples, obtained prior to surgery, to evaluate ctDNA levels in terms of mutant copy number/mL and variant allele frequency.<br/><br/>Results<br/>Somatic mutations were found in 24 tumors, of which seven were from patients with borderline, and 17 with invasive cancer diagnosis. TP53 was the most frequently mutated gene. Fifteen of 24 patients had detectable ctDNA levels in pre-operative plasma. Plasma ctDNA mutant concentration increased with higher stage (p_trend}},
  author       = {{Dobilas, Arturas and Leandersson, Pia and Chen, Yilun and Alcaide, Miguel and Brueffer, Christian and Saal, Lao and Borgfeldt, Christer}},
  issn         = {{1048-891X}},
  keywords     = {{Ovarian cancer; Gynecological cancer disease; Minimal residual disease; Liquid biopsy; ctDNA}},
  language     = {{eng}},
  month        = {{10}},
  note         = {{Conference Abstract}},
  number       = {{Suppl 2}},
  pages        = {{405--405}},
  publisher    = {{BMJ Publishing Group}},
  series       = {{International Journal of Gynecological Cancer}},
  title        = {{Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer}},
  url          = {{http://dx.doi.org/10.1136/ijgc-2022-ESGO.868}},
  doi          = {{10.1136/ijgc-2022-ESGO.868}},
  volume       = {{32}},
  year         = {{2022}},
}